MX9206563A - Utilizacion de derivados de anfotericina b como inhibidores de proteasas. - Google Patents

Utilizacion de derivados de anfotericina b como inhibidores de proteasas.

Info

Publication number
MX9206563A
MX9206563A MX9206563A MX9206563A MX9206563A MX 9206563 A MX9206563 A MX 9206563A MX 9206563 A MX9206563 A MX 9206563A MX 9206563 A MX9206563 A MX 9206563A MX 9206563 A MX9206563 A MX 9206563A
Authority
MX
Mexico
Prior art keywords
amphotericin
derivatives
protease inhibitors
pathogens
multiplication
Prior art date
Application number
MX9206563A
Other languages
English (en)
Inventor
Michel Seman
Original Assignee
Mayoly Spindler Lab
Michel Seman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayoly Spindler Lab, Michel Seman filed Critical Mayoly Spindler Lab
Publication of MX9206563A publication Critical patent/MX9206563A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Nueva utilización de la anfotericina b, o de un derivado de la misma, como inhibidor de proteasas. Aplicación para obtener medicamentos inhibidores de la multiplicación de agentes patógenos, en particular el VIH.
MX9206563A 1991-11-14 1992-11-13 Utilizacion de derivados de anfotericina b como inhibidores de proteasas. MX9206563A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9113999A FR2683723B1 (fr) 1991-11-14 1991-11-14 Nouveaux medicaments antiviraux actifs sur le virus vih.

Publications (1)

Publication Number Publication Date
MX9206563A true MX9206563A (es) 1993-11-01

Family

ID=9418894

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9206563A MX9206563A (es) 1991-11-14 1992-11-13 Utilizacion de derivados de anfotericina b como inhibidores de proteasas.

Country Status (10)

Country Link
US (1) US5514662A (es)
EP (1) EP0542630A3 (es)
JP (1) JPH06504295A (es)
KR (1) KR930702994A (es)
AU (1) AU669143B2 (es)
CA (1) CA2099490A1 (es)
FR (1) FR2683723B1 (es)
MX (1) MX9206563A (es)
TW (1) TW225991B (es)
WO (1) WO1993009791A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69333270T2 (de) 1992-03-11 2004-08-05 Narhex Ltd. Aminderivate von oxo- und hydroxy- substituierten kohlenwasserstoffen
US5888992A (en) 1992-03-11 1999-03-30 Narhex Limited Polar substituted hydrocarbons
RU2126794C1 (ru) 1992-03-11 1999-02-27 Нархекс Лимитед Аминопроизводные оксо- или гидроксизамещенных гидразинов, способ их получения и фармацевтические композиции для ингибирования ретровирусной протеазы
US6071895A (en) 1992-03-11 2000-06-06 Narhex Limited Polar-substituted hydrocarbons
US6869925B1 (en) 1992-09-09 2005-03-22 Amgen Inc. Inhibition of retrovirus infection
IL110898A0 (en) * 1993-09-10 1994-11-28 Narhex Australia Pty Ltd Polar-substituted hydrocarbons
US6017880A (en) * 1994-03-09 2000-01-25 Amgen Inc. Inhibition of retrovirus infection
GB2290707A (en) * 1994-06-28 1996-01-10 Georgi Stankov Pharmaceutical uses of Amphotericin B
GB2290708A (en) * 1994-06-28 1996-01-10 Georgi Stankov Pharmaceutical uses of polyene macrolides
US6413537B1 (en) 2000-03-10 2002-07-02 Wisconsin Alumni Research Foundation Nystatin formulation having reduced toxicity
JP2003327536A (ja) * 2002-03-07 2003-11-19 Kitasato Inst:The ヒト免疫不全症候群ウイルスの感染、増殖抑制剤
US20060194814A1 (en) * 2003-06-02 2006-08-31 Vassilios Papadopoulos Benzamide compounds
WO2005112922A2 (en) * 2004-04-22 2005-12-01 Samaritan Pharmaceuticals Benzamide compounds
CA2951516C (en) 2014-06-12 2019-04-02 Shionogi & Co., Ltd. Polyene macrolide derivative

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8829592D0 (en) * 1988-12-19 1989-02-08 Beecham Group Plc Novel compounds
EP0350164A3 (en) * 1988-06-13 1991-07-24 Beecham Group Plc Amphotericin derivatives
GB8829593D0 (en) * 1988-12-19 1989-02-08 Beecham Group Plc Novel compounds
US5175172A (en) * 1988-12-19 1992-12-29 Francois Dietlin Method of alleviating AIDS symptoms and compositions therefor
FR2654339B1 (fr) * 1989-11-14 1994-10-28 Mayoly Spindler Laboratoires Nouveaux derives solubles et non toxiques des macrolides polyeniques basiques, leur preparation et leurs applications.
EP0431874A1 (en) * 1989-12-08 1991-06-12 Beecham Group p.l.c. Novel compounds
EP0431870A1 (en) * 1989-12-08 1991-06-12 Beecham Group p.l.c. Amphotericin B derivatives
US5185366A (en) * 1990-07-31 1993-02-09 Ohio State University Research Foundation Method for treatment and prevention of diseases caused by enveloped viruses, including herpes simplex virus types 1 and 2 diseases, using 3,4-dihydroxy-2H-benzopyran-2H-one
US5120718A (en) * 1991-06-13 1992-06-09 Abbott Laboratories Candida acid protease inhibiting compounds
AU664857B2 (en) * 1991-08-14 1995-12-07 Sequus Pharmaceuticals, Inc. HIV-treatment method with low-toxicity amphotericin B

Also Published As

Publication number Publication date
FR2683723A1 (fr) 1993-05-21
WO1993009791A2 (fr) 1993-05-27
EP0542630A2 (fr) 1993-05-19
TW225991B (es) 1994-07-01
JPH06504295A (ja) 1994-05-19
WO1993009791A3 (fr) 1993-06-24
KR930702994A (ko) 1993-11-29
FR2683723B1 (fr) 1995-05-19
CA2099490A1 (fr) 1993-05-15
EP0542630A3 (en) 1993-08-04
AU669143B2 (en) 1996-05-30
US5514662A (en) 1996-05-07
AU3162893A (en) 1993-06-15

Similar Documents

Publication Publication Date Title
MX9206563A (es) Utilizacion de derivados de anfotericina b como inhibidores de proteasas.
AR005703A1 (es) Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen
ES2053778T3 (es) Procedimiento para la obtencion de derivados del tiazol.
ES2054860T5 (es) Derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion y su utilizacion como medicamentos.
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
ES2083668T3 (es) Combinaciones antiviricas que contienen analogos de nucleosidos.
DE69322390T2 (de) Absorbierder artikel mit slipseiten umgreifenden schutzelementen
AR021535A1 (es) Formas de dosificacion de liberacion controlada que comprenden zolpidem o sales del mismo
FI941222A (fi) Ei-peptidyyli-tyyppisiä integriini-inhibiittoreita, jotka ovat spesifisiä GPIIbIIIa-reseptorin suhteen
DK0813868T3 (da) Retrovirale proteaseinhibitorer
MX9202066A (es) Composiciones a base de acido graso para el control de infecciones establecidas en plantas.
SV2002000520A (es) Derivados de pirazol ref. pcs10927aajr/bb
MX9307821A (es) Nueva clase de inhibidores de proteasa aspartilo.
ES2089687T3 (es) 4-fenil-piridonas y 4-fenil-2-alcoxipiridinas sustituidas como inhibidores de la hmg-coa-reductasa.
ES2174921T3 (es) Inhibidores de la proteasa del vih.
ES2043665T3 (es) 6,11-dihidro-11-(4-piperidiliden)-5h-benzo-(5,6)-ciclohepta-(1,2-b)-piridinas y composiciones y metodos de uso.
MX9300399A (es) Derivados heterotriciclicos.
MX9302681A (es) Nuevas quinazolinas como inhibidores de transcriptasa inversa hiv.
AR013411A1 (es) Composicion de aplicacion para tratamientos antivirales y afecciones micosicas y/o bacterianas y utilizacion de dichas composiciones.
ES2125356T3 (es) Empleo de leflunomida para la inhibicion de interleuquina 8.
ATE108993T1 (de) Lichtschutz.
AR021463A1 (es) Antibiotico de piridona con perfil de seguridad mejorado
AR002957A1 (es) Una combinacion de compuestos utiles, su uso para preparar un medicamento, y una composicion y combinacion farmaceutica que los contienen.
UY27394A1 (es) Pedidos con actividad anti- angiogéna.
MX9204212A (es) Preparado de combinacion farmaceutico.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal